GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Momenta Pharmaceuticals Inc (NAS:MNTA) » Definitions » Equity-to-Asset

Momenta Pharmaceuticals (Momenta Pharmaceuticals) Equity-to-Asset : 0.76 (As of Jun. 2020)


View and export this data going back to 2004. Start your Free Trial

What is Momenta Pharmaceuticals Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Momenta Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2020 was $395.32 Mil. Momenta Pharmaceuticals's Total Assets for the quarter that ended in Jun. 2020 was $523.28 Mil. Therefore, Momenta Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Jun. 2020 was 0.76.

The historical rank and industry rank for Momenta Pharmaceuticals's Equity-to-Asset or its related term are showing as below:

MNTA' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.49   Med: 0.83   Max: 0.96
Current: 0.76

During the past 13 years, the highest Equity to Asset Ratio of Momenta Pharmaceuticals was 0.96. The lowest was -0.49. And the median was 0.83.

MNTA's Equity-to-Asset is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.59 vs MNTA: 0.76

Momenta Pharmaceuticals Equity-to-Asset Historical Data

The historical data trend for Momenta Pharmaceuticals's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Momenta Pharmaceuticals Equity-to-Asset Chart

Momenta Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 0.78 0.81 0.87 0.74

Momenta Pharmaceuticals Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.65 0.69 0.74 0.75 0.76

Competitive Comparison of Momenta Pharmaceuticals's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Momenta Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Momenta Pharmaceuticals's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Momenta Pharmaceuticals's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Momenta Pharmaceuticals's Equity-to-Asset falls into.



Momenta Pharmaceuticals Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Momenta Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Equity to Asset (A: Dec. 2019 )=Total Stockholders Equity/Total Assets
=454.46/618.365
=0.73

Momenta Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Jun. 2020 is calculated as

Equity to Asset (Q: Jun. 2020 )=Total Stockholders Equity/Total Assets
=395.317/523.279
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Momenta Pharmaceuticals  (NAS:MNTA) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Momenta Pharmaceuticals Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Momenta Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Momenta Pharmaceuticals (Momenta Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
301 Binney Street, Cambridge, MA, USA, 02142
Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including nipocalimab, M254, and M230, are in development to treat rare autoimmune diseases.
Executives
Bruce Downey director
Alejandra Carvajal officer: Chief Legal Officer C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Jose-carlos Gutierrez-ramos director C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Georges Gemayel director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Elizabeth Stoner director C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE MA 02142
Santiago Arroyo officer: SVP, Chief Medical Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Young Kwon officer: Chief Financial & Bus. Officer C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Ian Fier officer: Chief Mfg and Program Officer C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Jo Ann Beltramello officer: Chief HR and Inf. Officer C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Anthony M. Manning officer: Chief Scientific Officer C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Donna Roy Grogan director 1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Agnieszka Cieplinska officer: Chief Accounting Officer (PAO) C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Craig A Wheeler director, officer: President & CEO